Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
N Engl J Med. 2022;387(10):894–904 doi: 10.1056/NEJMoa2118025
Phase 2 study, in patients with systemic lupus erythematosus, shows that litifilimab is associated with a greater reduction from baseline in the number of swollen and tender joints than placebo, over a period of 24 weeks.
Furie, et al. investigate the efficacy and safety of litifilimab, a humanised IgG1 monoclonal antibody against blood dendritic cell antigen 2 (BDCA2), in patients with SLE who had both active arthritis and rash. This paper reports the findings from part A of the LILAC trial.